Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$103 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
--
ROE
0 %
ROCE
-164.04 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$229.45 Mln
EBITDA
$208.12 Mln
Net Profit
$-195.52 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
CalAmp (CAMP)
| -62.64 | -62.93 | -70.18 | -34.78 | -75.44 | -56.68 | -41.03 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
CalAmp (CAMP)
| -9.15 | -94.42 | -36.54 | -28.83 | 3.55 | -26.36 | -39.13 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 21.30 | 7,402.74 | -- | -103.82 | |
| 21.31 | 6,017.57 | -- | -0.13 | |
| 21.25 | 2,739.57 | -- | -1.14 | |
| 65.85 | 5,657.00 | -- | -1.18 |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial... for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: One Kendall Square, Cambridge, MA, United States, 02139 Read more
Senior VP & CFO
Mr. Jikun Kim
Senior VP & CFO
Mr. Jikun Kim
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CalAmp Corp (CAMP) stood at -- as on 31-Dec-24
The share price of CalAmp Corp (CAMP) is $1.95 (NASDAQ) as of 22-Apr-2025 16:00 EDT. CalAmp Corp (CAMP) has given a return of -75.44% in the last 3 years.
CalAmp Corp (CAMP) has a market capitalisation of $ 103 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of CalAmp Corp (CAMP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CalAmp Corp (CAMP) and enter the required number of quantities and click on buy to purchase the shares of CalAmp Corp (CAMP).
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: One Kendall Square, Cambridge, MA, United States, 02139
The CEO & director of Mr. Jikun Kim. is CalAmp Corp (CAMP), and CFO & Sr. VP is Mr. Jikun Kim.
There is no promoter pledging in CalAmp Corp (CAMP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
709
|
|
|
633
|
|
|
569
|
|
|
569
|
| CalAmp Corp. (CAMP) | Ratios |
|---|---|
|
Return on equity(%)
|
-82.02
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-7943.4
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CalAmp Corp (CAMP) was No Profit.
$0.05
(
